Revenue and net profit grew 24.40% and 21.84% year-over-year, driven by strong performance in both pharmaceutical and high-temperature alloy segments. The company advanced R&D, completed a major share buyback, and established a ¥1 billion M&A fund.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.